A preclinical study of a PI3K/mTOR dual inhibitor in the treatment of esophageal adenocarcinoma.

被引：0
|
作者：
Omstead, Ashten N.
Zaidi, Ali Hussainy
Kosovec, Juliann E.
Matsui, Daisuke
Raj, Moses S.
Biederman, Robert W. W.
Finley, Gene Grant
Kelly, Ronan Joseph
Jobe, Blair A.
机构：
[1] Allegheny Hlth Network, Esophageal & Lung Inst, Pittsburgh, PA USA
[2] Allegheny Hlth Network, McGinnis Cardiovascular Inst, Pittsburgh, PA USA
[3] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e15554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15554
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma
    Larsen, Jeremy T.
    Ramakrishnan, Vijay
    Haug, Jessica
    Kimlinger, Teresa
    Sen, Somdutta
    Mahajan, Dinesh
    Dugar, Sundeep
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    CANCER RESEARCH, 2015, 75
  • [2] Apitolisib. Dual PI3K/mTOR inhibitor, Oncolytic
    de Lartigue, Jane
    DRUGS OF THE FUTURE, 2013, 38 (10) : 671 - 678
  • [3] A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
    Sun, Xin
    Yang, Yang
    Xia, Lulu
    Wang, Shiyu
    Fu, Yuxing
    Zhu, Yuxuan
    Xu, Shan
    Zhu, Wufu
    Zhu, Wufu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [4] Dual targeting of pi3k/mTOR
    Fokas, E.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S43 - S43
  • [5] PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model
    Zaidi, Ali H.
    Kosovec, Juliann E.
    Matsui, Daisuke
    Omstead, Ashten N.
    Raj, Moses
    Rao, Rohit R.
    Biederman, Robert W. W.
    Finley, Gene G.
    Landreneau, Rodney J.
    Kelly, Ronan J.
    Jobe, Blair A.
    ANNALS OF SURGERY, 2017, 266 (01) : 91 - 98
  • [6] Treatment of Waldenstrom Macroglobulinemia with a Dual PI3K and mTOR Inhibitior
    Husu, E. N.
    Roccaro, A. M.
    Mohler, M. J.
    Ghobrial, I. M.
    Sacco, A.
    Melhem, M. R.
    Azab, A.
    Jia, X.
    Ngo, H. T.
    Azab, F.
    Rennels, J.
    Quang, P.
    Leleu, X.
    Mohler, M. J.
    Ghobrial, I. M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2009, 57 : S154 - S154
  • [7] PRECLINICAL STUDIES OF THE PI3K/MTOR DUAL INHIBITOR, PF-04691502, IN BREAST CANCER CELL LINES
    Kan, J.
    Yuan, J.
    Lee, N.
    Pavlicek, A.
    Ching, K.
    Cao, J.
    Garza, S.
    Hook, K.
    Christensen, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 55 - 55
  • [8] Preclinical PKPD modeling and human dose projection of PF-046915027, a PI3K/mTOR dual inhibitor
    Luu, Kenneth T.
    Zhang, Eric
    Bagrodia, Shubha
    Yuan, Jing
    CANCER RESEARCH, 2010, 70
  • [9] Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
    Jin, Ning
    Jiang, Tianyun
    Rosen, David M.
    Nelkin, Barry D.
    Ball, Douglas W.
    CLINICAL CANCER RESEARCH, 2011, 17 (20) : 6482 - 6489
  • [10] Early preclinical development of PQR309, a novel balanced dual PI3K/mTOR inhibitor for treatment of various cancer types
    Ettlin, R.
    Dieterle, W.
    Fabbro, D.
    Hebeisen, P.
    Beaufils, F.
    Hillmann, P.
    Stumm, M.
    Dimitrijevic, S.
    Wymann, M.
    Cmiljanovic, N.
    Giese, B.
    Cmiljanovic, V.
    TOXICOLOGY LETTERS, 2015, 238 (02) : S337 - S338
12345